Organization

The Pillar Biosciences leadership team consists of genomics innovators who are passionate about making precision NGS panels accessible to labs to enable real-time individualized patient management.

Leadership Team

Gang Song PhD Founder & Chief Executive Officer

Gang is a visionary genomics innovator and co-founder of Pillar Biosciences. He subsequently founded Affyimmune Therapeutics, a cellular immunotherapy company. [more]

Gang is a visionary genomics innovator and co-founder of Pillar Biosciences. He subsequently founded Affyimmune Therapeutics, a cellular immunotherapy company. Previously, Gang was a Technical Lead at Integrated Genetics, LabCorp (previously Genzyme Genetics). Gang completed his postdoctoral training in Timothy Springer's lab at Harvard Medical School and received his PhD from Shanghai Medical College of Fudan University, China.

Zhaohui Wang PhD Co-founder and Chief Science Officer

Zhaohui is the NGS technology inventor of SLIMamp™ and formerly she was an Associate Vice President at Integrated Genetics in the genomics laboratory at Lab Corp (previously Genzyme) [more]

Zhaohui is the NGS technology inventor of SLIMamp™. Formerly she was an Associate Vice President at Integrated Genetics in the genomics laboratory at Lab Corp (previously Genzyme). Zhaohui received her PhD in Cellular and Molecular biology at the University of Massachusetts, Amherst and her undergraduate degree from Peking University, China.

Manfred Scholz PhD, MBA Head of Corporate Development

Manfred has more than 30 years' clinical diagnostics experience. His strategic and operational management experience includes CEO at Prolias LLC and President and COO at Stem Cell Preservation Technologies. [more]

Manfred has more than 30 years' clinical diagnostics experience. His strategic and operational management experience includes CEO at Prolias LLC and President and COO at Stem Cell Preservation Technologies. He was also VP Business Development at IQuum (now Roche), Senior Director Business Development at Large Scale Biology. Senior Consultant at Boston Biomedical Consultants, and various development and global product management positions at Dade Behring (now Siemens). Manfred was a research fellow at the Max-Planck Institute for Biophysics and Harvard University. He received a PhD in Physics from Goethe University in Frankfurt, Germany, and an MBA from Babson College, Wellesley, Massachusetts.

Brian Dugan Head of Product Management

Previously at QIAGEN he worked in multiple capacities including lead of NGS Strategic Marketing for QIAGEN's QIAseq portfolio. As QIAGEN's product manager Brian was responsible for multiple product launches across PCR and NGS product lines. [more]

Brian has held multiple positions working in Next Generation Sequencing in both clinical and life science segments. Previously at QIAGEN he worked in multiple capacities including lead of NGS Strategic Marketing for QIAGEN's QIAseq portfolio and as a product manager responsible for multiple product launches across PCR and NGS product lines. At Personalis as part of the launch commercial team, he developed business opportunities on the East Coast including projects with INOVA hospital, Mayo Hospitals and the Kennedy Krieger Institute. At EdgeBio, he launched one of the first CLIA Exome services for clinical and pharma customers in the US. Brian has a MS in Biochemistry and Molecular Biology from Georgetown University and an BS from University of Maryland, College Park.

Scientific Advisory Board

Cheng-Zhong Zhang PhD Cofounder and Advisory Board Member

Cheng-Zhong combines single cell genomics and cell biology to study genome evolution and phenotypic variation in cancer cells. [more]

Cheng-Zhong combines single cell genomics and cell biology to study genome evolution and phenotypic variation in cancer cells. Previously he was a postdoctoral fellow working on single-molecule biophysics at Harvard Medical School (Timothy Springer's Lab) and subsequently worked on single cell genomics and cancer cell biology at Broad Institute and Dana-Farber Cancer Institute (Matthew Meyerson's Lab). He holds a PhD in Chemical Engineering with a minor in Physics from Caltech.

Timothy Springer PhD Professor, Harvard Medical School

Immunologist best known for pioneering work in discovery of the first integrins and intercellular adhesion molecules (ICAMs) and their function in the immune system. [more]

Immunologist best known for pioneering work in discovery of the first integrins and intercellular adhesion molecules (ICAMs) and their function in the immune system. Additional research interest has expanded to include malaria, transforming growth factor beta (TGF-β) signaling molecules, and von Willebrand factor. A member of the National Academy of Sciences and the American Academy of Arts and Sciences. University of California, Berkeley, a PhD in Molecular Biology and Biochemistry from Harvard University.

Paul Waring MBBS, PhD, FRCPA, FRCPath, FHGSA, FFSc(RCPA) Professor of Pathology, University of Melbourne

Paul is an anatomical, molecular and translational pathologist who is a pioneer in the application of molecular and genomic technologies to cancer diagnostics and cancer drug development. [more]

Paul is an anatomical, molecular and translational pathologist who is a pioneer in the application of molecular and genomic technologies to cancer diagnostics and cancer drug development. Previously, Paul served in various senior academic and industry positions including Director of Pathology at the Peter MacCallum Cancer Centre in Melbourne Australia, Senior Director of Pathology and Diagnostics at Genentech, USA, Chair of Pathology at the University of Melbourne, and Vice President of Medical Innovation at Roche Diagnostics USA. He has published over 140 scientific articles and abstracts, and served on numerous committees and advisory boards in the fields of cancer molecular pathology and personalized medicine. He earned an MBBS degree from the University of Western Australia, completed anatomic pathology training at the Queen Elizabeth II Medical Centre in Western Australia and a PhD in Cancer Biology from the Walter and Eliza Hall Institute at the University of Melbourne.

Marcia Eisenberg PhD Chief Science Officer and Sr. VP LabCorp

Currently oversees Research and Development, Science and Technology including test development, optimization and automation as well as Licensing and Business Development. [more]

Currently oversees Research and Development, Science and Technology including test development, optimization and automation as well as Licensing and Business Development. Marcia has developed hundreds of clinical assays used for patient care during her 25 plus years at LabCorp. She earned a BS in biology, a BA in psychology, and an MS in Molecular Biology from the State University of New York at Albany and a PhD in Molecular Biology from the University of Kentucky.

Investors

Ori Fund

A $200 million venture capital fund focused on investing in innovative companies with disruptive technologies in the healthcare industry globally. [more]

A $200 million venture capital fund focused on investing in innovative companies with disruptive technologies in the healthcare industry globally. The fund is founded by Ms. Simone Song, former investment banker at Goldman Sachs.

Zhen Fund

A Beijing-based seed fund with a portfolio of over 150 high growth companies within technology. [more]

A Beijing-based seed fund with a portfolio of over 150 high growth companies within technology. ZhenFund was established in 2011 in collaboration with Sequoia Capital China, with the aim of promoting innovation among youth in China. After empowering Chinese students to study abroad, Bob and Victor are now dedicated to helping returnees pursue entrepreneurship in China.

Shenzhen Oriental Fortune Capital Co Ltd.

A venture capital firm specializing investment in stages from early venture to mature capital raises. [more]

A venture capital firm specializing investment in stages from early venture to mature capital raises. The firm typically invests in a broad consumer goods to telecommunications to healthcare, life sciences and pharmaceutical or biological medicine.